%PDF-1.4
%
46 0 obj
<>
endobj
43 0 obj
<>
endobj
92 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-12T10:51:21Z
2024-03-29T01:03:09-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T01:03:09-07:00
application/pdf
Heather
2004-502.dec
uuid:aee94e9c-1dd1-11b2-0a00-d60927edca00
uuid:aee94e9f-1dd1-11b2-0a00-380000000000
endstream
endobj
32 0 obj
<>
endobj
33 0 obj
<>
endobj
47 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 18 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 20 0 R/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 22 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 24 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 26 0 R/Type/Page>>
endobj
110 0 obj
[114 0 R]
endobj
111 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6229 0.7822 -0.7822 0.6229 12.739 54.1879 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
12 789 587 -785 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 73.368 737.5293 Tm
[(Hansen HE. Cyclosporin )54.8 (A)-220.1 (treatment of systemic sclerosis. Br )]TJ
0 -1.25 TD
(J Dermatol 1990;122:677-81.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (White B, Moore )17.7 (WC, )17.7 (W)39.8 (igley FM, Xiao HQ, )17.7 (W)39.8 (ise RA.)]TJ
2.175 -1.25 Td
(Cyclophosphamide is associated with pulmonary function and )Tj
T*
[(survival benefit in patients with scleroderma and alveolitis. )54.8 (Ann)]TJ
T*
(Intern Med 2000;132:947-54.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Lin )54.8 (A)110.8 (TH, Clements PJ, Furst DE. Update on disease-modifying)]TJ
2.175 -1.25 Td
(antirheumatic drugs in the treatment of systemic sclerosis. Rheum)Tj
0 Tc T*
[(Dis Clin North )54.8 (Am 2003;29:409-26. )]TJ
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875.1 (Giacomelli R, )17.7 (V)110.8 (alentini G, Salsano F)79.7 (, et al. Cyclophosphamide)]TJ
2.175 -1.25 Td
(pulse regimen in the treatment of alveolitis in systemic sclerosis. )Tj
T*
(J Rheumatol 2002;29:731-6.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous)]TJ
2.175 -1.25 Td
(stem cell transplantation in systemic sclerosis: procedure related)Tj
T*
[(mortality and impact on skin disease. )54.8 (Ann Rheum Dis )]TJ
0 Tc 0 Tw T*
(2001;60:577-84.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875.1 (Khorshid O, Hosing C, Bibawi S, et al. Nonmyeloablative stem cell)]TJ
2.175 -1.25 Td
(transplant in a patient with advanced systemic sclerosis and)Tj
T*
(systemic lupus erythematosus. J Rheumatol 2004;31:2513-6.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (Nash RA, McSweeney P)91.7 (A, Storb R, et al. )17.7 (T)35 (reatment of severe )]TJ
2.175 -1.25 Td
(systemic sclerosis with allogeneic marrow transplantation)Tj
T*
([abstract]. Blood 2002;100 Suppl 1:460b.)Tj
-2.175 -1.25 Td
[(20.)-875.1 (Davas EM, Peppas C, Maragou M, )54.8 (Alvanou E, Hondros D, Dantis)]TJ
2.175 -1.25 Td
[(P)110.8 (. Intravenous cyclophosphamide pulse therapy for the treatment of)]TJ
T*
(lung disease associated with scleroderma. Clin Rheumatol)Tj
0 Tc 0 Tw T*
(1999;18:455-61.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(21.)-875.1 (van Bekkum DW)91.7 (. Ef)17.7 (fectiveness and risks of total body irradiation)]TJ
2.175 -1.25 Td
(for conditioning in the treatment of autoimmune disease with )Tj
T*
(autologous bone marrow transplantation. Rheumatology)Tj
0 Tc 0 Tw T*
(1999;38:757-61.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875.1 (Bensinger )17.7 (WI, Spielber)17.7 (ger)39.7 (, R. Preparative regimens and )]TJ
2.175 -1.25 Td
(modification of regimen-related toxicities. In: Blume KH, Forman)Tj
T*
[(SJ, )54.8 (Appelbaum FR, editors. )17.7 (Thomas\325)-201.1 (hematopoietic cell )]TJ
T*
(transplantation. 3rd ed. London: Blackwell Publishing; 2004:158.)Tj
-2.175 -1.25 Td
[(23.)-875.1 (Far)17.7 (ge D, Marolleau JP)110.7 (, Zohar S, et al. )54.8 (Autologous bone marrow)]TJ
2.175 -1.25 Td
(transplantation in the treatment of refractory systemic sclerosis:)Tj
T*
[(early results from a French multicentre phase I-II study)64.8 (. Br )]TJ
T*
[(J Haematol 2002;1)36.8 (19:726-39.)]TJ
-2.175 -1.25 Td
[(24. )-600.1 (Nash RA, Bowen JD, McSweeney P)91.7 (A, et al. High-dose )]TJ
2.175 -1.25 Td
(immunosuppressive therapy and autologous peripheral blood stem)Tj
33 48.75 Td
(cell transplantation for severe multiple sclerosis. Blood)Tj
0 Tc 0 Tw T*
(2003;102:2364-72.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(25.)-875.1 (V)110.8 (a)0.3 (r)17.7 (ga J, Haustein UF)79.7 (, Creech RH, Dwyer JP)110.7 (, Jimenez SA.)]TJ
2.175 -1.25 Td
(Exaggerated radiation-induced fibrosis in patients with systemic)Tj
0 Tc T*
[(sclerosis. JAMA)-220.1 (1991;265:3292-5.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(26.)-875.1 (Sanders JE. Growth and development after hematopoietic cell )]TJ
2.175 -1.25 Td
[(transplantation. In: Blume KH, Forman SJ, )54.8 (Appelbaum FR, editors.)]TJ
T*
[(Thomas\325)-201.1 (hematopoietic cell transplantation. 3rd ed. London:)]TJ
T*
(Blackwell Publishing; 2004:929-47.)Tj
-2.175 -1.25 Td
[(27.)-875.1 (Sanders JE, Buckner CD, )54.8 (Amos D, et al. Ovarian function )]TJ
2.175 -1.25 Td
(following marrow transplantation for aplastic anemia or leukemia. )Tj
T*
(J Clin Oncol 1988;6:813-8.)Tj
-2.175 -1.25 Td
[(28.)-875.1 (Sanders JE, Buckner CD, Leonard JM, et al. Late ef)17.7 (fects on)]TJ
2.175 -1.25 Td
(gonadal function of cyclophosphamide, total-body irradiation, and)Tj
T*
[(marrow transplantation. )17.7 (T)35 (ransplantation 1983;36:252-5.)]TJ
-2.175 -1.25 Td
[(29.)-875.1 (Flowers MED, Deeg JD. Delayed complications after )]TJ
2.175 -1.25 Td
(hematopoietic cell transplantation. In: Blume KH, Forman SJ,)Tj
T*
[(Appelbaum FR, editors. )17.7 (Thomas\325)-201.1 (hematopoietic cell )]TJ
T*
(transplantation. 3rd ed. London: Blackwell Publishing; 2004:944.)Tj
-2.175 -1.25 Td
[(30.)-875.1 (Curtis RE, Rowlings P)91.7 (A, Deeg HJ, et al. Solid cancers after bone)]TJ
2.175 -1.25 Td
(marrow transplantation. N Engl J Med 1997;336:897-904.)Tj
-2.175 -1.25 Td
[(31.)-875.1 (Kolb HJ, Socie G, Duell )17.7 (T)74 (, et al. Malignant neoplasms in long-term)]TJ
2.175 -1.25 Td
[(survivors of bone marrow transplantation. Late Ef)17.7 (fects )17.7 (W)79.9 (orking)]TJ
T*
(Party of the European Cooperative Group for Blood and Marrow)Tj
T*
[(T)35 (ransplantation and the European Late Ef)17.7 (fect Project Group. )54.8 (Ann)]TJ
T*
(Intern Med 1999;131:738-44.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (Baker KS, DeFor )17.7 (TE, Burns LJ, Ramsay NK, Neglia JP)110.7 (, Robison)]TJ
2.175 -1.25 Td
(LL. New malignancies after blood or marrow stem-cell )Tj
T*
(transplantation in children and adults: incidence and risk factors. )Tj
T*
(J Clin Oncol 2003;21:1352-8.)Tj
-2.175 -1.25 Td
[(33. )-600.1 (Stone RM, Neuber)17.7 (g D, Soif)17.7 (fer R, et al. Myelodysplastic syndrome)]TJ
2.175 -1.25 Td
(as a late complication following autologous bone marrow )Tj
T*
[(transplantation for non-Hodgkin\325)54.8 (s lymphoma. J Clin Oncol)]TJ
0 Tc 0 Tw T*
(1994;12:2535-42.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(34.)-875.1 (Krishnan )54.8 (A, Bhatia S, Slovak ML, et al. Predictors of )]TJ
2.175 -1.25 Td
(therapy-related leukemia and myelodysplasia following autologous)Tj
T*
(transplantation for lymphoma: an assessment of risk factors. Blood)Tj
0 Tc 0 Tw T*
(2000;95:1588-93.)Tj
ET
0 0 0 1 K
52.97 77 m
557.97 77 l
S
0 0 0 0 k
493.79 69.86 64.18 -15.66 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
8 0 0 8 540.968 56.9344 Tm
(2335)Tj
ET
0 0 0 0 k
53.03 71 203 -15.66 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.032 58.0696 Tm
(Furst, et al: Editorial)Tj
ET
0 0 0 0 k
/GS0 gs
102.09 81.75 407.5 -10.83 re
f*
0.5 w
102.09 81.75 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
112.368 73 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
26 0 obj
<>stream
8;Z\7$#[X7%+G5@kjPTl-'Igr-eSnBK8D34C/"pb;-PISrsJIGRD%Ka:]FO(@8Xf6
0>c4n^>;?pj'\JhF&m0[F7Vmo.Pc`Y4Dn/K*u96gie^)Z0IW'KB4JdIaIQ/rY*:"O
FA\HI0f/G%`ge@9^spjUb0=YZ#9C1@rjZC_WCG?02`^:Ir;[+C:1`PZs$A,[Cr#oZ)DO274Sf&G)AM4mm0_d8ffX/O9]K4OHZq;9g_)
*4gQSWXM0:nPi(Y;Q27=YG/bX3:3`*T[]f(Oc+Ki/n<.`,8As0JLWE@l%3M9rZN,<
SWIJ'giW,A4)9M["S4[Spu*]aPaf'1u_=`FqZML.W*o)KIfg"K42+GEf:`UR\O[<$sQec
Q.Qr/i*Pl39(spq*YO;o3&ilW3&ilWpib9l9YEOu^FLu8n+$bI0A;$rIKfeO6JU`~>
endstream
endobj
30 0 obj
[/Indexed/DeviceRGB 255 29 0 R]
endobj
29 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
81 0 obj
<>
endobj
51 0 obj
<>
endobj
55 0 obj
<>
endobj
70 0 obj
<>
endobj
97 0 obj
<>
endobj
54 0 obj
<>
endobj
62 0 obj
<>stream
HUkTSW7{<.IJ: "
Z;-*A Q+G!BB@"ABtU*>ZQ)3ȴyDY1k>[g}
q9dT{<.EU~=Yb< W6SX{R{bކۻPOؤg;7hφy02舑8Ωm]A'KZbMe05%HE
\*lI+KqrQ@"x+HE24˚}}bX&ȥq 8i@O*N"AP .-aD*[d2q8N*~}?c5,́(l)yJl=f 1:=H=,K¾LacUs@xfD"K)g@`9/llgٵ=#^hs^Ἶy3{9d8ӱqi!8khJl?_ Gzjd\۠a8EUXVk#Yvj,WU&WFel+(Mh9l4K$OnaŽo%`ŃNYӼ\2Evg_jվfZ|!g!lꕏX5mEc3UL6bVp6Zrg^0:M^c>K^LxJ*L[/硽om93vdg,W/L@jeX]VͦÛw
"L蘫6W=:4e^-m'ۏLf ԡR wd92u[ȱH7:=0Q!6s*/V+;-Oo?o0?6g} M ަ2hƚWkZcw =˟
b?M},l"SWI
8L("gCiIMxBrU8woLŇF5(<@ԛB6uM2S\֨5i55:X!`ac>тͭ'B6-`<
)jiMx嚣1륉ɆI